Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

This article was originally published in Scrip

Executive Summary

Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.

You may also be interested in...



Sanofi/Regeneron Choose Access Over Price With Dupixent Launch

The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.

10 Approvals To Watch For In Early 2017

Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.

Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

UsernamePublicRestriction

Register

SC064872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel